2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139419
    Bimatoprost grenod 1194396-71-8 98.34%
    Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
    Bimatoprost grenod
  • HY-142059
    PDE5-IN-4 224788-36-7 99.60%
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.
    PDE5-IN-4
  • HY-148136
    sEH inhibitor-7 340221-20-7 99.50%
    sEH inhibitor-7 (compound c-2) is an inhibitor of soluble epoxide hydrolase (sEH) with IC50s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation.
    sEH inhibitor-7
  • HY-14834A
    Budiodarone tartrate 478941-93-4 99.31%
    Budiodarone (ATI-2042) tartrate is a chemical analogue of Amiodarone (HY-14187) with balanced, multiple cardiac ion channel (potassium, sodium and calcium channels) inhibiting activity. Budiodarone tartrate is an antiarrhythmic agent.
    Budiodarone tartrate
  • HY-148908
    TNF-α-IN-8 444287-85-8
    TNF-α-IN-8 (compound I-42) is a TNF-α inhibitor. TNF-α-IN-8 is an isoindole-imide compound. TNF-α-IN-8 can be used for the research of cancer, heart disease, osteoporosis, inflammatory, allergic and autoimmune diseases. TNF-α-IN-8 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    TNF-α-IN-8
  • HY-152086
    DRP1i27 1453028-33-5 99.36%
    DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.
    DRP1i27
  • HY-152106
    BAY-7081 3036022-06-4 99.03%
    BAY-7081, a chemical probe, is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM.
    BAY-7081
  • HY-153115
    Plasma kallikrein-IN-4 1357954-34-7 98.61%
    Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein.
    Plasma kallikrein-IN-4
  • HY-15556A
    GSK269962A hydrochloride 2095432-71-4 99.73%
    GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
    GSK269962A hydrochloride
  • HY-155988
    Sirtuin modulator 6 476633-98-4 99.70%
    Sirtuin modulator 6 (compound 262) increases the lifespan of a cell. Sirtuin modulator 6 can be used for study of diabetes, obesity, neurodegenerative diseases, cardiovascular disease, and so an extracted from patent WO2009064913A1.
    Sirtuin modulator 6
  • HY-161104
    Kv2.1-IN-1 2252448-93-2 98.64%
    Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC50 of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K+, Na+, and Ca2+ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H2O2. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke.
    Kv2.1-IN-1
  • HY-162322
    VU0542270 1396814-79-1 98.48%
    VU0542270 is a selective vascular Kir6.1/SUR2B KATP channel inhibitor with an IC50 value of 100 nM. VU0542270 has an IC50 > 30 μM for the other nine members of the Kir channel family. VU0542270 can be used in the study of cardiovascular disease.
    VU0542270
  • HY-162558
    NCGC00351170 886536-76-1 99.05%
    NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation.
    NCGC00351170
  • HY-163438
    BKIDC-1553 1951431-34-7 99.65%
    BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research.
    BKIDC-1553
  • HY-167712
    (2R,3S)-Azelaprag 2049979-31-7 99.10%
    (2R,3S)-Azelaprag ((2R,3S)-AMG 986) (Example 238.0) is a precursor of an apelin receptor agonist (EC50=12 nM) and an isomer of Azelaprag (HY-109111).
    (2R,3S)-Azelaprag
  • HY-172942
    SP11 2629218-24-0 98.91%
    SP11 is a mitochondrial reactive oxygen species (ROS) inhibitor. SP11 activates Fis1 by binding to Cys41 (IC50: 9.4 µM) and increases the translocation of Drp1 to mitochondria. SP11 can be used in studies on the protection against oxidative stress damage.
    SP11
  • HY-173162
    GPV0057 86383-89-3 99.20%
    GPV0057 (Compound 5d) is a selective and potent P-glycoprotein (P-gp) inhibitor. GPV0057 is also a selective potassium channel Kir2.1 activator. GPV0057 competitively binds to the substrate-binding site of P-gp, inhibiting ATP-dependent drug efflux to reverse multidrug resistance in tumor cells. GPV0057 can also stabilizes the open state of Kir2.1 and promotes potassium ion influx. GPV0057 is promising for research of tumors with high P-gp expression, Kir2.1-deficient diseases such as heart failure and Andersen-Tawil Syndrome.
    GPV0057
  • HY-17512S
    Losartan-d4 1030937-27-9 99.93%
    Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
    Losartan-d4
  • HY-19414A
    (R)-MLN-4760 305335-29-9 99.51%
    (R)-MLN-4760, the R-enantiomer of MLN-4760, is an ACE2 inhibitor, with an IC50 of 8.4 μM. (R)-MLN-4760 is the less active isomer.
    (R)-MLN-4760
  • HY-40136S
    cis-4-Hydroxy-L-proline-d3 ≥99.0%
    cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension.
    cis-4-Hydroxy-L-proline-d3
Cat. No. Product Name / Synonyms Application Reactivity